A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

耐受性 医学 硼替佐米 内科学 胃肠病学 养生 抗坏血酸 多发性骨髓瘤 耐火材料(行星科学) 临床研究阶段 外科 恶心 无症状的 不利影响 毒性 化学 物理 天体生物学 食品科学
作者
James R. Berenson,Jeffrey Matous,Regina A. Swift,Russell Mapes,Blake Morrison,Howard Yeh
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:13 (6): 1762-1768 被引量:119
标识
DOI:10.1158/1078-0432.ccr-06-1812
摘要

Abstract Purpose: This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy in patients with relapsed/refractory multiple myeloma. Experimental Design: Enrolled in six cohorts, patients were given arsenic trioxide (0.125 or 0.250 mg/kg), bortezomib (0.7, 1.0, or 1.3 mg/m2), and a fixed dose of ascorbic acid (1 g) i.v. on days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles. The primary end point was safety/tolerability of the ABC regimen. Results: Twenty-two patients (median age, 63 years) were enrolled, having failed a median of 4 (range, 3-9) prior therapies. One occurrence of grade 4 thrombocytopenia was observed. One patient had asymptomatic arrhythmia and withdrew from the study. Objective responses were observed in 6 (27%) patients, including two partial responses and four minor responses. Median progression-free survival was 5 months (95% confidence interval, 2-9 months), and median overall survival had not been reached. The 12-month progression-free survival and overall survival rates were 34% and 74%, respectively. One (minor response) of six patients receiving the lowest dose of bortezomib (0.7 mg/m2) and 5 (2 partial responses and 3 minor responses) of 16 patients receiving the higher doses (1.0 or 1.3 mg/m2) responded. Conclusions: The ABC regimen was well tolerated by most patients, and it produced preliminary signs of efficacy with an objective response rate of 27% in this heavily pretreated study population. These findings warrant further clinical evaluation of the ABC combination for treatment of relapsed/refractory multiple myeloma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
断梗浮萍完成签到,获得积分10
刚刚
刚刚
刚刚
刚刚
2秒前
2秒前
狱颖发布了新的文献求助30
3秒前
沐小蕾完成签到 ,获得积分10
3秒前
ZCX完成签到,获得积分10
4秒前
科研助手6应助JMao采纳,获得10
4秒前
shiplec发布了新的文献求助10
4秒前
ZHANG完成签到,获得积分10
5秒前
111111发布了新的文献求助10
5秒前
传奇3应助SHJ采纳,获得10
5秒前
5秒前
5秒前
小太爷发布了新的文献求助10
5秒前
翻斗花园小美完成签到,获得积分10
6秒前
6秒前
zho应助hmy采纳,获得10
6秒前
Hello应助re采纳,获得10
7秒前
一一完成签到 ,获得积分10
7秒前
Monicadd完成签到 ,获得积分10
7秒前
阿良发布了新的文献求助10
7秒前
8秒前
老衲完成签到,获得积分10
8秒前
8秒前
hl完成签到,获得积分10
9秒前
孙了了完成签到,获得积分10
9秒前
9秒前
Akim应助江恪采纳,获得10
9秒前
yangzhuang发布了新的文献求助10
9秒前
9秒前
CEJ发布了新的文献求助10
10秒前
Pomelo发布了新的文献求助10
10秒前
10秒前
11秒前
橙橙橙发布了新的文献求助10
11秒前
11秒前
12秒前
高分求助中
Chinesen in Europa – Europäer in China: Journalisten, Spione, Studenten 500
Arthur Ewert: A Life for the Comintern 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi // Kurt Werner Radtke 500
Two Years in Peking 1965-1966: Book 1: Living and Teaching in Mao's China // Reginald Hunt 500
Epigenetic Drug Discovery 500
Hardness Tests and Hardness Number Conversions 300
Knowledge management in the fashion industry 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3816654
求助须知:如何正确求助?哪些是违规求助? 3360106
关于积分的说明 10406570
捐赠科研通 3078132
什么是DOI,文献DOI怎么找? 1690563
邀请新用户注册赠送积分活动 813815
科研通“疑难数据库(出版商)”最低求助积分说明 767883